

LISTING AND AMENDMENT OF THE CLAIMS:

1. (Previously presented) A method for screening a selective inhibitor of COX-2 for functionality in addition to COX-2 protein inhibition, comprising screening for at least one COX protein inhibition independent therapeutic activity.

2. (Previously presented) The method of screening of Claim 1 which comprises screening the selective inhibitor of COX-2 for at least two of (a) activation of PPRE luciferase by at least 100%, (b) at least 50% decrease in level of or 50% downregulation of expression of Class I family of receptors tyrosine kinase, (c) at least 50% downregulation of expression of cyclin D1, (d) at least 50% downregulation of expression of HPV16 oncoproteins E6 and E7, (e) at least 50% increase in expression of PTEN, (f) at least 50% inhibition of tcf/lef/-catenin-mediated promoter activation, and (g) at least 50% increase in level of Nrf-2.

3. – 5. (Canceled)